From the Centers for Disease Control and Prevention. Use of short-course tuberculosis preventive therapy regimens in HIV-seronegative persons.
D000995:Antitubercular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D018023:HIV Seronegativity; D006801:Humans; D017410:Practice Guidelines as Topic; D011718:Pyrazinamide / Q000008:administration & dosage / Q000627:therapeutic use*; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use*; D014376:Tuberculosis / Q000517:prevention & control*
D000995:Antitubercular Agents; D011718:Pyrazinamide; D012293:Rifampin